Denosumab for the Treatment of Therapy-Induced Bone Loss in Non-Metastatic Prostate Cancer (terminated appraisal) (TA194)

Technology Appraisal Guidance No. 194

Source: National Institute for Health and Care Excellence

NICE is unable to recommend the use in the NHS of denosumab for the treatment of therapy-induced bone loss in people with non-metastatic prostate cancer because no evidence submission was received from the manufacturer or sponsor of the technology.

A copy of the full document and background is available on the Internet at

This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

© Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.

Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA.

Denosumab for the treatment of therapy-induced bone loss in non-metastatic prostate cancer (terminated appraisal)
Issue Date: July 2010

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in